The Journey of an Oral Drug
When a drug is swallowed, it faces a gauntlet of barriers before reaching systemic circulation. First, it must dissolve and cross the intestinal epithelium (fraction absorbed, fa). Next, enzymes in the gut wall (especially CYP3A4 and UGT) can metabolize it before it even enters the portal vein (gut wall survival, fg). Finally, the portal blood delivers the drug directly to the liver, where extensive metabolism can destroy much of the remaining dose (hepatic survival, fh).
Quantifying Bioavailability
Oral bioavailability F equals the product fa × fg × fh. Each factor is independent and multiplicative. Even if gut absorption is excellent (fa = 0.95), a drug with high hepatic extraction (fh = 0.1) will have only ~10% bioavailability. This is why some drugs require enormously higher oral doses compared to IV doses — most of the oral dose never reaches the target tissue.
First-Pass Metabolism
The first-pass effect is a consequence of portal circulation anatomy: all venous blood from the GI tract flows through the liver before reaching the heart and systemic circulation. Drugs administered IV, sublingually, rectally (partially), or transdermally bypass this hepatic filter. The clinical impact is dramatic — oral nitroglycerin is almost useless due to >90% first-pass extraction, but sublingual nitroglycerin is rapidly effective.
Improving Bioavailability
Pharmaceutical scientists employ multiple strategies to improve F: prodrug design (ester prodrugs that are activated after absorption), lipid-based formulations (enhancing lymphatic absorption to bypass portal circulation), enzyme inhibitors (ritonavir boosting in HIV therapy), and nanoparticle formulations (increasing dissolution rate). Each approach targets a specific bottleneck in the absorption cascade visualized in this simulation.